Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1637 1642 1643 1644 1646
This examiner grants 74% of resolved cases
Amy Marie Chattin is an examiner in Tech Center 1600 and Art Unit 1637. The examiner has 53 resolved cases. This number of resolutions provides a focused look at the examiner's prosecution history. The data set allows practitioners to observe the examiner's approach to patentability and the typical outcomes for applications in this specific technology area.
The allowance rate is 73.6 percent. This figure indicates the proportion of resolved cases that have resulted in a patent grant. The median days to allowance is 1384. This duration represents the time required for an application to move through the examination process to a successful conclusion. Applicants can use this figure to plan their intellectual property timelines and budget for the prosecution phase.
The interview lift is 44.0 percent. This indicates that an interview is associated with a significant increase in the probability of an allowance. The positive lift suggests that direct communication is a highly effective method for overcoming rejections with this examiner. Practitioners should consider an interview as a primary strategy for clarifying technical points and advancing the application toward a grant.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18612141 | USES OF IL-13 ANTAGONISTS FOR TREATING ATOPIC DERMATITIS | Non-Final OA | GENENTECH, INC. |
| 18553143 | ANTIBODIES AGAINST CLEAVED CDCP1 AND USES THEREOF | Non-Final OA | The Regents of the University of California |
| 18248189 | MOTIF NEOEPITOPES FOR CANCER IMMUNOTHERAPY | Final Rejection | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA |
| 17773283 | DEGRADATION OF SURFACE PROTEINS USING BISPECIFIC BINDING AGENT | Non-Final OA | The Regents of the University of California |
| 18252928 | ANTI-CD6 ANTIBODY CONJUGATES FOR TREATING T-CELL MEDIATED DISORDERS AND T-CELL LYMPHOMA/LEUKEMIA | Final Rejection | The Cleveland Clinic Foundation |
| 18560746 | CHIMERIC POLYPEPTIDES AND METHODS OF USE | Non-Final OA | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM |
| 18066529 | PROTEASE-ACTIVATED T CELL BISPECIFIC ANTIBODIES | Non-Final OA | Hoffmann-La Roche Inc. |
| 18451671 | DETECTION OF ACUTE MYELOID LEUKAEMIA | Final Rejection | OXFORD UNIVERSITY INNOVATION LIMITED |
| 17777659 | STIMULI THAT HYPERACTIVATE RESIDENT DENDRITIC CELLS FOR CANCER IMMUNOTHERAPY | Final Rejection | Children's Medical Center Corporation |
| 17997161 | TREATMENT AND PREVENTION OF CANCER USING VIRUS-SPECIFIC IMMUNE CELLS EXPRESSING CHIMERIC ANTIGEN RECEPTORS | Non-Final OA | Baylor College of Medicine |
| 18481725 | COMPOSITIONS AND METHODS OF TREATING CANCER WITH CHIMERIC ANTIGEN RECEPTORS TARGETING CLAUDIN 18.2 | Non-Final OA | MEDIMMUNE, LLC |
| 17755278 | INTRATUMORAL ADMINISTRATION OF IMMUNE CELLULAR THERAPEUTICS | Final Rejection | FIGENE, LLC |
| 18566424 | CANCER TREATMENT METHOD BY COMBINED USE OF CD47 INHIBITORY SUBSTANCE, IMMUNE CHECKPOINT INHIBITORY SUBSTANCE, AND STANDARD THERAPY | Non-Final OA | ONO PHARMACEUTICAL CO., LTD. |
| 17624502 | A PHARMACEUTICAL COMPOSITION FOR TREATING HEMATOLOGICAL CANCER | Non-Final OA | ONO PHARMACEUTICAL CO., LTD. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy